Novo Nordisk $NOVO B (-2,31%) will present new semaglutide data on:
- “Food noise” reduction
- Body composition
- Cardiovascular benefits
- Plus updates from the pipeline
Not just weight loss – semaglutide continues to show broad metabolic & cardiovascular impact. Potential bullish catalyst ahead.
